Table 4. Oligoprogressive castration-resistant prostate cancer: results of the univariate analyses concerning DPFS and second-line STFS.
| Median DPFS (months) | 1-year DPFS | 2-year DPFS | 3-year DPFS | Median STFS | 1-year STFS | 2-year STFS | 3-year STFS | |
|---|---|---|---|---|---|---|---|---|
| Whole population (41 pts) | 11.2 | 43.2% | 21.6% | 11.9% | 22 | 74.8% | 41.3% | 29.5% |
| Initial Gleason Score | P=0.611 | P=0.382 | ||||||
| ⩽7 | 15 | 54.4% | 27.3% | n.r. | 28 | 83.3% | 52.9% | 17.6% |
| >7 | 7 | 34.3% | 11.4% | n.r. | 14 | 57.1% | 28.6% | n.r. |
| D'Amico risk group (D'Amico et al, 1998) | P=0.15 | P=0.096 | ||||||
| Intermediate/high | 24 | 72% | 43.3% | 34.7% | 28 | 85.6% | 64.2% | 42.8% |
| Very high | 7 | 30.7% | 12.3% | 6.1% | 19 | 71.1% | 35.5% | 26.7% |
| PSA pre-SBRT | P=0.644 | P=0.643 | ||||||
| <4 ng ml−1 | 11 | 41.2% | 12% | 12% | 22 | 74.2% | 33.4% | 22.3% |
| ⩾4 ng ml−1 | 11 | 43.9% | 31.4% | 16.7% | 23 | 64.4% | 38.9% | 18.4% |
| Time to castrate resistant | P=0.941 | P=0.39 | ||||||
| <37 months | 14 | 50.5% | 14.4% | 14.4% | 22 | 63.5% | 42.3% | 21.2% |
| ⩾37 months | 11 | 37.2% | 26.6% | n.r. | 19 | 83.3% | 38.2% | n.r. |
| Lymph node vs bone | P=0.791 | P=0.34 | ||||||
| Lymph | 11 | 42.1% | 21.1% | 16.8% | 22 | 80.7% | 43.5% | 34.8% |
| Bone | 6 | 45.7% | 22.9% | 0% | 19 | 75% | 47.7% | 35.8% |
| Number of metastases | P=0.43 | P=0.40 | ||||||
| One | 11 | 44% | 24% | 15% | 24 | 74.6% | 47% | 33.6% |
| More than one | 11 | 42.9% | 14.3% | 14.3% | 22 | 77.1% | 19.3% | n.r. |
| BED | P=0.721 | P=0.238 | ||||||
| <116 Gy | 8 | 31.5% | 21.0% | n.r. | 23 | 90.9% | 45.5% | 40.8% |
| ⩾116 Gy | 11 | 49.4% | 22.4% | 18% | 19 | 67.5% | 38.6% | 23.1% |
Abbreviations: BED=biologically effective dose; DPFS=distant progression-free survival; FS=free survival; n.r.=not reached; PSA=prostatic-specific antigen; SBRT=stereotactic body radiation therapy; STFS=systemic treatment-free survival.